Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression

As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time- and dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription factor TEA domain 1 (TEAD1) and plays an important role in cell proliferation and survival. However, the role of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Acta Pharm Sin B
Hlavní autoři: Wang, Panxia, Wang, Minghui, Hu, Yuehuai, Chen, Jianxing, Cao, Yanjun, Liu, Cui, Wu, Zhongkai, Shen, Juan, Lu, Jing, Liu, Peiqing
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7982427/
https://ncbi.nlm.nih.gov/pubmed/33777675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2020.10.017
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky